Moderna has announced the expansion of its US manufacturing capabilities with the onshoring of drug product manufacturing to its existing Moderna Technology Center ("MTC") in Norwood, Massachusetts.
Through this strategic onshoring, Moderna will now operate full end-to-end manufacturing for its mRNA medicines in the US.
This milestone marks a significant step in strengthening Moderna's US manufacturing network, supporting both commercial and clinical supply and reinforcing the Company's commitment to domestic mRNA production.
"By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the US," said Stéphane Bancel, CEO of Moderna.
"As an American company committed to building and producing in America, we are proud to strengthen our domestic footprint while bringing meaningful new jobs to the community."
The expansion reflects Moderna's ongoing investment in US-based infrastructure and its commitment to building a robust, domestic manufacturing platform capable of supporting its pipeline of mRNA vaccines and therapeutics.
Moderna's innovative mRNA platform, first recognised globally during the company's partnership with the US Government through Operation Warp Speed, continues to drive potential biomedical breakthroughs across infectious diseases, cancer, rare diseases and autoimmune disorders.
Construction at MTC for the new Drug Product manufacturing capability has started, with Moderna targeting completion by the first half of 2027.